Press Release
iRhythm Technologies Announces First Quarter 2017 Financial Results
First Quarter 2017 Financial Results
- Revenue for the quarter ended
March 31, 2017 increased 67% year-over-year to$21.4 million - Gross margin for the first quarter 2017 was 70% versus 64% in the first quarter of 2016
First Quarter 2017 Business Highlights
The American College of Cardiology (ACC), theAmerican Heart Association (AHA), and theHeart Rhythm Society (HRS) jointly issued a new guideline that recommends the use of cardiac monitors such as the Zio Service when evaluating patients with syncope (fainting).The National Institute for Health and Care Excellence (NICE) in theU.K. issued a publication citing evidence that demonstrates the high diagnostic yield of the company’s Zio Service compared to the Holter monitor.- The results of a study comparing detection rates of atrial fibrillation between the company's Zio Service and the Holter monitor in patients following stroke was accepted as a late-breaking clinical trial oral presentation at the 3rd
European Stroke Organisation Conference , to be held inPrague onMay 18, 2017 .
"Adoption of our Zio Service continued at a strong pace in the first quarter. While taking a highly disciplined and measured approach to hiring, we made substantial progress expanding our sales organization, and have now nearly completed building out our sales management and support infrastructure. In addition, we were also successful in expanding reimbursement coverage and contracts with commercial payors to increase patient access,” said
First Quarter Financial Results
Revenue for the three months ended
Gross profit for the first quarter of 2017 was
Operating expenses for the first quarter of 2017 were
Loss from operations for the first quarter of 2017 was
Cash, cash equivalents, and investments totaled
Guidance for Full Year 2017
iRhythm projects revenue for the full year 2017 to range from
Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at
About
iRhythm is a commercial-stage digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our Form 10-K filing made with the
IRHYTHM TECHNOLOGIES, INC. | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
(Unaudited) | ||||||||
(In thousands) | ||||||||
March 31, 2017 | December 31, 2016 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $15,583 | $51,643 | ||||||
Short-term investments | 77,397 | 54,407 | ||||||
Accounts receivable, net | 10,982 | 9,406 | ||||||
Inventory | 1,156 | 1,390 | ||||||
Prepaid expenses and other current assets | 1,388 | 1,671 | ||||||
Restricted cash | 91 | 91 | ||||||
Total current assets | 106,597 | 118,608 | ||||||
Investments, long-term | 16,429 | 10,981 | ||||||
Property and equipment, net | 5,529 | 4,653 | ||||||
Goodwill | 862 | 862 | ||||||
Other assets | 3,384 | 3,052 | ||||||
Total assets | $132,801 | $138,156 | ||||||
Liabilities, Convertible Preferred Stock and Stockholders’ Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $1,413 | $2,103 | ||||||
Accrued liabilities | 8,284 | 10,165 | ||||||
Deferred revenue | 980 | 947 | ||||||
Total current liabilities | 10,677 | 13,215 | ||||||
Debt | 32,652 | 32,227 | ||||||
Deferred rent, noncurrent portion | 26 | 26 | ||||||
Accrued interest, net of current portion | 134 | 126 | ||||||
Total liabilities | 43,489 | 45,594 | ||||||
Stockholders’ equity: | ||||||||
Common stock | 27 | 22 | ||||||
Additional paid-in capital | 221,776 | 219,718 | ||||||
Accumulated other comprehensive loss | (19 | ) | (9 | ) | ||||
Accumulated deficit | (132,472 | ) | (127,169 | ) | ||||
Total stockholders’ equity | 89,312 | 92,562 | ||||||
Total liabilities, convertible preferred stock and stockholders’ equity | $132,801 | $138,156 | ||||||
IRHYTHM TECHNOLOGIES, INC. | ||||||||
Condensed Consolidated Statements of Operations | ||||||||
(Unaudited) | ||||||||
(In thousands, except share and per share data) | ||||||||
Three Months Ended March 31, |
||||||||
2017 | 2016 | |||||||
Revenue | $21,437 | $12,854 | ||||||
Cost of revenue | 6,337 | 4,659 | ||||||
Gross profit | 15,100 | 8,195 | ||||||
Operating expenses: | ||||||||
Research and development | 2,621 | 1,545 | ||||||
Selling, general and administrative | 17,224 | 11,521 | ||||||
Total operating expenses | 19,845 | 13,066 | ||||||
Loss from operations | (4,745 | ) | (4,871 | ) | ||||
Interest expense | (822 | ) | (795 | ) | ||||
Other expense, net | 264 | (460 | ) | |||||
Net loss | $(5,303 | ) | $(6,126 | ) | ||||
Net loss per common share, basic and diluted | $(0.24 | ) | $(4.34 | ) | ||||
Weighted-average shares used to compute net loss per common share, | ||||||||
basic and diluted | 22,151,926 | 1,413,052 | ||||||
Investor Relations Contact:Lynn Pieper Lewis orLeigh Salvo (415) 937-5404 investors@irhythmtech.com Media ContactAaron Murphy (415) 229-3331 media@irhythmtech.com